G1 Therapeutics, Inc. (GTHX) Tops Q4 EPS by 7c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts GTHX Hot Sheet
Join SI Premium – FREE
G1 Therapeutics, Inc. (NASDAQ: GTHX) reported Q4 EPS of ($0.21), $0.07 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $14.87 million versus the consensus estimate of $13.08 million.
GUIDANCE:
G1 Therapeutics, Inc. sees FY2024 revenue of $60-70 million, versus the consensus of $66.25 million.
For earnings history and earnings-related data on G1 Therapeutics, Inc. (GTHX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- AI-powered cyber threats light a fire under cybersecurity stocks
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
